Myristoleic acid

Research use only, not for human use.

Myristoleic acid is a cytotoxic component in the extract from Serenoa repens. Myristoleic acid induces apoptosis and necrosis in human prostatic LNCaP cells.

Myristoleic acid is a cytotoxic component in the extract from Serenoa repens. Myristoleic acid induces apoptosis and necrosis in human prostatic LNCaP cells.(In Vitro):Myristoleic acid induces both necrosis (100 μg/mL, 81.8%) and apoptosis (100 μg/mL, 89.5%) in LNCaP cells . Myristoleic acid inhibited RANKL-induced osteoclast formation in vitro, especially, at later stages of differentiation. (In Vivo):Myristoleic acid (2 mg/kg, IP every 24 h for 4 days) prevents RANKL-induced bone loss and osteoclast formation in mice .

Myristoleic acid induces both apoptosis (100 μg/mL, 89.5%) and necrosis (100 μg/mL, 81.8%) in LNCaP cells. Myristoleic acid inhibited RANKL-induced osteoclast formation in vitro, especially, at later stages of differentiation. Cell Proliferation Assay Cell Line:Human prostatic carcinoma LNCaP cells.Concentration:0, 50, 100, 150, 200, 250 μg/mL.Incubation Time:24 h.Result:When LNCaP cells were treated with 130 μg/mL extract or 100 μg/mL myristoleic acid for 24 hr, the proportion of apoptotic cells was 16.5 and 8.8%, and that of necrotic one was 46.8 and 81.8%, respectively.

Myristoleic acid (2 mg/kg, IP every 24 h for 4 days) prevents RANKL-induced bone loss and osteoclast formation in mice. Animal Model:C57BL/6 mice at 5 weeks. Dosage:0.2, 2 mg/kg Administration:IP every 24 h for 4 days.Result:Co-administration of myristoleic acid suppressed generation of TRAP-positive osteoclasts induced by sRANKL and attenuated the increases in osteoclastic indices of Oc.S/BS, N.Oc/B. Pm and ES/BS in a dose-dependent manner.

(Z)-Tetradec-9-enoic acid | cis-9-tetradecenoic acid | 9-Tetradecenoic acid

Apoptosis

Apoptosis

SARS-CoV-2

——

——

544-64-9

226.36

C14H26O2

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (441.77 mM)

CCCC\C=C/CCCCCCCC(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years